Aptus Pharma IPO was subscribed 22.27 times on the last day. A retail quota was subscribed over 31.43 times, NII was subscribed over 28.75 times, and QIB was subscribed 1.24 times, respectively.
Details About Aptus Pharma IPO
Aptus Pharma IPO received approval from SEBI for an IPO worth ₹13.02 crores, wherein a fresh issue would be totally ₹13.02 crores with a face value of ₹10 each.
Further, the Aptus Pharma IPO had a set price band of ₹65 to ₹70 per share.
Aptus Pharma IPO consists of 4,000 shares in 2 lot sizes for retail minimum and maximum categories as well. While 6,000 shares were in 3 lot sizes for the S-HNI category. S-HNI Maximum received 14,000 shares in 7 lot sizes. B-HNI Minimum got 16,000 shares in 8 lot sizes.
To invest in the Aptus Pharma IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum and maximum investment of ₹2,80,000.
- SHNI (S-HNI): Minimum investment of ₹4,20,000.
- SHNI (S-HNI): Maximum investment of: ₹9,80,000.
- B-HNI Minimum: Maximum investment of: ₹11,20,000.
Aptus Pharma IPO Subscription Duration
Aptus Pharma IPO opened on September 23, 2025, and closed on September 25, 2025. The Aptus Pharma IPO allotment date was scheduled on September 26, 2025. The Aptus Pharma IPO listing date is on September 30, 2025.
Aptus Pharma IPO funds deployment
- The proceeds raised from the fresh issue will be used for the purchase of Office Premises with furniture and Industrial Racks
- Some funds will be used for the Working Capital Requirement of the Company.
- Lastly, the remaining funds will be for the general corporate purposes.
About Aptus Pharma IPO Company
One of the growing companies in the marketing and selling of pharmaceutical products, Aptus Pharma, was founded in 2010. Aptus Pharma is engaged in the manufacture and distribution of a broad range of pharmaceutical formulations covering multiple therapeutic areas: antacids & PPIs, pain management, anti-inflammatories, antibiotics, cardiology & antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, sachets, and more.
The company works with many healthcare professionals in different areas, including general doctors, child specialists, women’s health doctors, heart specialists, diabetes doctors, brain specialists, and others. The company has various promoters, wherein Mr. Tejash Maheshchandra Hathi has more than 20 years of experience in the pharmaceutical industry.
Financial Report of the Aptus Pharma IPO Company
The company reported revenue of ₹24.64 crores in 2025 against ₹17.88 crores in 2024. The company reported a profit of ₹3.10 crores in 2025 against a profit of ₹0.80 crores in 2024.
